CA2433384A1 - Neurotrophic tacrolimus analogs - Google Patents
Neurotrophic tacrolimus analogs Download PDFInfo
- Publication number
- CA2433384A1 CA2433384A1 CA002433384A CA2433384A CA2433384A1 CA 2433384 A1 CA2433384 A1 CA 2433384A1 CA 002433384 A CA002433384 A CA 002433384A CA 2433384 A CA2433384 A CA 2433384A CA 2433384 A1 CA2433384 A1 CA 2433384A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- injury
- nerve
- spinal cord
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000000508 neurotrophic effect Effects 0.000 title claims abstract description 16
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 title abstract description 24
- 150000001875 compounds Chemical class 0.000 claims abstract description 103
- 230000006378 damage Effects 0.000 claims abstract description 32
- 208000014674 injury Diseases 0.000 claims abstract description 29
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 26
- 230000004064 dysfunction Effects 0.000 claims abstract description 17
- 230000001537 neural effect Effects 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims description 34
- 210000004027 cell Anatomy 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 19
- 210000005036 nerve Anatomy 0.000 claims description 19
- 239000003981 vehicle Substances 0.000 claims description 19
- 238000011084 recovery Methods 0.000 claims description 18
- 210000000278 spinal cord Anatomy 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 210000000578 peripheral nerve Anatomy 0.000 claims description 14
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 12
- 206010029240 Neuritis Diseases 0.000 claims description 12
- 208000024827 Alzheimer disease Diseases 0.000 claims description 11
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 11
- 229940053128 nerve growth factor Drugs 0.000 claims description 11
- 230000001737 promoting effect Effects 0.000 claims description 11
- 208000020431 spinal cord injury Diseases 0.000 claims description 11
- 210000001519 tissue Anatomy 0.000 claims description 11
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 10
- 230000005709 nerve cell growth Effects 0.000 claims description 10
- 201000001119 neuropathy Diseases 0.000 claims description 9
- 230000007823 neuropathy Effects 0.000 claims description 9
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 9
- 230000012010 growth Effects 0.000 claims description 8
- 208000005987 polymyositis Diseases 0.000 claims description 8
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 7
- 238000002512 chemotherapy Methods 0.000 claims description 7
- 210000002569 neuron Anatomy 0.000 claims description 7
- 230000004936 stimulating effect Effects 0.000 claims description 7
- 239000006285 cell suspension Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 239000005022 packaging material Substances 0.000 claims description 6
- 238000011069 regeneration method Methods 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 206010033799 Paralysis Diseases 0.000 claims description 5
- 230000003376 axonal effect Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000008929 regeneration Effects 0.000 claims description 5
- 208000027530 Meniere disease Diseases 0.000 claims description 4
- 206010027910 Mononeuritis Diseases 0.000 claims description 4
- 206010036105 Polyneuropathy Diseases 0.000 claims description 4
- 206010037779 Radiculopathy Diseases 0.000 claims description 4
- 206010039966 Senile dementia Diseases 0.000 claims description 4
- 201000004810 Vascular dementia Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000013734 mononeuritis simplex Diseases 0.000 claims description 4
- 201000005518 mononeuropathy Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 208000021090 palsy Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 208000019629 polyneuritis Diseases 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 239000003076 neurotropic agent Substances 0.000 claims description 3
- 239000000651 prodrug Substances 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 230000007514 neuronal growth Effects 0.000 claims description 2
- 208000028389 Nerve injury Diseases 0.000 claims 5
- 230000008764 nerve damage Effects 0.000 claims 5
- 208000032984 Intraoperative Complications Diseases 0.000 claims 2
- 230000001900 immune effect Effects 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 230000008736 traumatic injury Effects 0.000 claims 2
- 210000005013 brain tissue Anatomy 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 22
- 241000700159 Rattus Species 0.000 description 22
- 229960001967 tacrolimus Drugs 0.000 description 18
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 18
- 238000007920 subcutaneous administration Methods 0.000 description 15
- 238000011201 multiple comparisons test Methods 0.000 description 12
- 210000002241 neurite Anatomy 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 238000001543 one-way ANOVA Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- -1 Compound (I) Chemical class 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 210000003141 lower extremity Anatomy 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 210000003497 sciatic nerve Anatomy 0.000 description 7
- 210000003050 axon Anatomy 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 210000003371 toe Anatomy 0.000 description 6
- 206010029260 Neuroblastoma Diseases 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 210000002683 foot Anatomy 0.000 description 5
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 3
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 3
- 229960003132 halothane Drugs 0.000 description 3
- 210000004295 hippocampal neuron Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000009689 neuronal regeneration Effects 0.000 description 3
- 230000002276 neurotropic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 108090000099 Neurotrophin-4 Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000014511 neuron projection development Effects 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 210000004116 schwann cell Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000006373 Bell palsy Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000025962 Crush injury Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- 208000010188 Folic Acid Deficiency Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102000000521 Immunophilins Human genes 0.000 description 1
- 108010016648 Immunophilins Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical class [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- 102100029268 Neurotrophin-3 Human genes 0.000 description 1
- 102000003683 Neurotrophin-4 Human genes 0.000 description 1
- 102100033857 Neurotrophin-4 Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 241000097929 Porphyria Species 0.000 description 1
- 208000010642 Porphyrias Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229940117913 acrylamide Drugs 0.000 description 1
- 150000003926 acrylamides Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- NOFOAYPPHIUXJR-APNQCZIXSA-N aphidicolin Chemical compound C1[C@@]23[C@@]4(C)CC[C@@H](O)[C@@](C)(CO)[C@@H]4CC[C@H]3C[C@H]1[C@](CO)(O)CC2 NOFOAYPPHIUXJR-APNQCZIXSA-N 0.000 description 1
- SEKZNWAQALMJNH-YZUCACDQSA-N aphidicolin Natural products C[C@]1(CO)CC[C@]23C[C@H]1C[C@@H]2CC[C@H]4[C@](C)(CO)[C@H](O)CC[C@]34C SEKZNWAQALMJNH-YZUCACDQSA-N 0.000 description 1
- 208000030137 articulation disease Diseases 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000000256 facial nerve Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002684 laminectomy Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- 238000007491 morphometric analysis Methods 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 101150006061 neur gene Proteins 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 231100000878 neurological injury Toxicity 0.000 description 1
- 230000006764 neuronal dysfunction Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000003209 petroleum derivative Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 201000008752 progressive muscular atrophy Diseases 0.000 description 1
- 230000001141 propulsive effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000002972 tibial nerve Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 208000002670 vitamin B12 deficiency Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Saccharide Compounds (AREA)
- Packages (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25850000P | 2000-12-29 | 2000-12-29 | |
| US60/258,500 | 2000-12-29 | ||
| PCT/US2001/050419 WO2002053159A1 (en) | 2000-12-29 | 2001-12-31 | Neurotrophic tacrolimus analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2433384A1 true CA2433384A1 (en) | 2002-07-11 |
Family
ID=22980816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002433384A Abandoned CA2433384A1 (en) | 2000-12-29 | 2001-12-31 | Neurotrophic tacrolimus analogs |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1353671A4 (cs) |
| JP (1) | JP2004527472A (cs) |
| KR (2) | KR20070030331A (cs) |
| CN (1) | CN1293877C (cs) |
| AR (1) | AR035411A1 (cs) |
| AU (1) | AU2002231277B2 (cs) |
| BR (1) | BR0116762A (cs) |
| CA (1) | CA2433384A1 (cs) |
| CZ (1) | CZ20032060A3 (cs) |
| HU (1) | HUP0302521A3 (cs) |
| IL (1) | IL156664A0 (cs) |
| MX (1) | MXPA03005941A (cs) |
| NO (1) | NO20032913D0 (cs) |
| NZ (1) | NZ527209A (cs) |
| PL (1) | PL366301A1 (cs) |
| RU (1) | RU2288716C2 (cs) |
| WO (1) | WO2002053159A1 (cs) |
| ZA (1) | ZA200305806B (cs) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003901023A0 (en) * | 2003-03-04 | 2003-03-20 | Fujisawa Pharmaceutical Co., Ltd. | New use |
| KR20060125849A (ko) * | 2004-01-20 | 2006-12-06 | 아스텔라스세이야쿠 가부시키가이샤 | 발기부전 치료 방법 |
| EP1810675A1 (en) * | 2006-01-18 | 2007-07-25 | Institut Curie | Method for treating Huntington's disease by inhibiting dephosphorylation of huntingtin at S421 |
| JP2009102226A (ja) * | 2006-02-14 | 2009-05-14 | Meiji Milk Prod Co Ltd | 脊髄損傷治療剤 |
| DK2307007T3 (da) | 2008-07-23 | 2014-11-10 | Novartis Ag | Sphingosin-1-phosphat-receptormodulatorer samt deres anvendelse til behandling af muskelinflammation |
| JP2015511242A (ja) * | 2012-02-23 | 2015-04-16 | インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラリシェルシェ メディカル） | 病変性前庭障害の治療に使用するカルシニューリン阻害剤 |
| GB201309375D0 (en) * | 2013-05-24 | 2013-07-10 | Chronos Therapeutics Ltd | Medical methods and compounds for medical use |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US537663A (en) * | 1895-04-16 | wubstee | ||
| JP2799208B2 (ja) * | 1987-12-09 | 1998-09-17 | フアイソンズ・ピーエルシー | マクロ環状化合物 |
| GR1001225B (el) * | 1989-09-14 | 1993-06-30 | Fisons Plc | Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους. |
| US5534520A (en) * | 1990-04-10 | 1996-07-09 | Fisher; Abraham | Spiro compounds containing five-membered rings |
| US5541193A (en) * | 1991-09-05 | 1996-07-30 | Abbott Laboratories | Heterocycle-containing macrocyclic immunomodulators |
| GB9202196D0 (en) * | 1992-02-01 | 1992-03-18 | Fisons Plc | Method of treatment |
| GB9218027D0 (en) * | 1992-08-25 | 1992-10-14 | Fisons Plc | Novel method of treatment |
| US5696135A (en) * | 1995-06-07 | 1997-12-09 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth |
| US5968921A (en) * | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
| GB9917158D0 (en) * | 1999-07-21 | 1999-09-22 | Fujisawa Pharmaceutical Co | New use |
-
2001
- 2001-12-27 AR ARP010106058A patent/AR035411A1/es unknown
- 2001-12-31 CZ CZ20032060A patent/CZ20032060A3/cs unknown
- 2001-12-31 EP EP01991558A patent/EP1353671A4/en not_active Withdrawn
- 2001-12-31 HU HU0302521A patent/HUP0302521A3/hu unknown
- 2001-12-31 CN CNB018228860A patent/CN1293877C/zh not_active Expired - Fee Related
- 2001-12-31 JP JP2002554109A patent/JP2004527472A/ja not_active Ceased
- 2001-12-31 KR KR1020077003889A patent/KR20070030331A/ko not_active Ceased
- 2001-12-31 CA CA002433384A patent/CA2433384A1/en not_active Abandoned
- 2001-12-31 WO PCT/US2001/050419 patent/WO2002053159A1/en not_active Ceased
- 2001-12-31 IL IL15666401A patent/IL156664A0/xx unknown
- 2001-12-31 BR BR0116762-6A patent/BR0116762A/pt not_active Application Discontinuation
- 2001-12-31 KR KR1020037008787A patent/KR100794204B1/ko not_active Expired - Fee Related
- 2001-12-31 NZ NZ527209A patent/NZ527209A/en unknown
- 2001-12-31 AU AU2002231277A patent/AU2002231277B2/en not_active Ceased
- 2001-12-31 PL PL01366301A patent/PL366301A1/xx not_active Application Discontinuation
- 2001-12-31 MX MXPA03005941A patent/MXPA03005941A/es active IP Right Grant
- 2001-12-31 RU RU2003123493/15A patent/RU2288716C2/ru not_active IP Right Cessation
-
2003
- 2003-06-24 NO NO20032913A patent/NO20032913D0/no not_active Application Discontinuation
- 2003-07-28 ZA ZA2003/05806A patent/ZA200305806B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20032913D0 (no) | 2003-06-24 |
| EP1353671A1 (en) | 2003-10-22 |
| EP1353671A4 (en) | 2004-07-14 |
| WO2002053159A1 (en) | 2002-07-11 |
| IL156664A0 (en) | 2004-01-04 |
| RU2003123493A (ru) | 2005-01-20 |
| HUP0302521A2 (hu) | 2003-11-28 |
| KR100794204B1 (ko) | 2008-01-14 |
| KR20070030331A (ko) | 2007-03-15 |
| AR035411A1 (es) | 2004-05-26 |
| JP2004527472A (ja) | 2004-09-09 |
| NZ527209A (en) | 2005-09-30 |
| CN1538843A (zh) | 2004-10-20 |
| PL366301A1 (en) | 2005-01-24 |
| ZA200305806B (en) | 2005-01-26 |
| AU2002231277B2 (en) | 2006-11-30 |
| CN1293877C (zh) | 2007-01-10 |
| BR0116762A (pt) | 2004-08-10 |
| HUP0302521A3 (en) | 2007-03-28 |
| RU2288716C2 (ru) | 2006-12-10 |
| KR20040007431A (ko) | 2004-01-24 |
| CZ20032060A3 (cs) | 2004-01-14 |
| MXPA03005941A (es) | 2005-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cui et al. | CNTF, not other trophic factors, promotes axonal regeneration of axotomized retinal ganglion cells in adult hamsters. | |
| Tator | Biology of neurological recovery and functional restoration after spinal cord injury | |
| Gaviria et al. | Neuroprotective effects of a novel NMDA antagonist, Gacyclidine, after experimental contusive spinal cord injury in adult rats | |
| KR100298808B1 (ko) | 외상손상과관련된신경학적병변의치료를위한,릴루졸을포함하는제약학적조성물 | |
| MX2009002063A (es) | Tratamiento de desordenes en cartilagos con factor de crecimiento de fibroblastos-18. | |
| LT4516B (lt) | Rotamazės fermento inhibitoriai | |
| US5580555A (en) | Regeneration of injured central nervous system axons | |
| DE69635754T2 (de) | Medikamente zur verhinderung von eingriffsbedingter stenose als folge von nicht-bypass invasiver eingriffe | |
| KR20010032357A (ko) | 신경 퇴화의 예방 및 신경 재생의 촉진을 위한 치환된아미노메틸 크로만의 용도 | |
| KR20200101948A (ko) | 신경계 질환 치료제 | |
| AU2002231277B2 (en) | Neurotrophic tacrolimus analogs | |
| AU2002231277A1 (en) | Neurotrophic tacrolimus analogs | |
| CN1310622A (zh) | 丙戊酸类似物在治疗和预防偏头痛与情感性疾病中的应用 | |
| Hitzenberger et al. | Pharmacological properties of piracetam: Rationale for use in stroke patients | |
| US20040077676A1 (en) | Neurotrophic tacrolimus analogs | |
| EP0305181A2 (en) | Ethyl-(+)-apovincaminate for treating demyelinization clinical patterns of autoimmune origin | |
| DE69531166T2 (de) | Arzneistoff zur erleichterung der durch immunsuppressiva verursachten nebenwirkungen | |
| Itoh et al. | The effect of neurotrophic pyrimidine heterocyclic compounds, MS-818 and MS-430, on the regeneration of injured peripheral nerves | |
| CA2455896A1 (en) | Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma | |
| US6852496B1 (en) | Methods of screening for agents that promote nerve cell growth | |
| Saunders et al. | Degeneration and regeneration in the nervous system | |
| JP2009504636A (ja) | 血漿または血清を含む神経損傷治療用の医薬組成物 | |
| RU2825666C2 (ru) | Терапевтическое средство для лечения заболевания нервной системы | |
| US20180311191A1 (en) | New combination therapies for treating neurological damage | |
| CN1270727C (zh) | 一种治疗脊髓损伤的治疗剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |